AUTHORS
Ji Hyun Lee, MD, PhD, Elham Ashrafi2, Cameron Wellard3, Nicholas Weber, MBBS4, Hang Quach, MBBS MD FRACP FRCPA5, Peter Mollee, MBBS, MSc, FRACP, FRCPA6, Erica Wood7, Andrew Spencer, MBBS FRACP FRCPA DM8
AFFILIATIONS
1 Dana-Farber Cancer Institute, The Jerome Lipper Multiple Myeloma Center,, Boton, Massachusetts, United States, Dong-A University College of Medicine, Busan, Korea, Rep. of South
2 Alfred Health-Monash University,, Melbourne, Australia
3 Alfred Health-Monash University,, Melbourne, Australia
4 Royal Brisbane and Women’s Hospital, Herston, Australia
5 St Vincent’s Hospital Melbourne, Melbourne, Australia
6 Princess Alexandra Hospital, Woolloongaba, Australia
7 Alfred Health-Monash University,, Melbourne, Australia
8 Alfred Health-Monash University,, Melbourne, Australia
ABSTRACT
Introduction: CD38 monoclonal antibodies (mAbs) improve outcomes in multiple myeloma (MM), but across the Asia-Pacific (APAC) and Australia & New Zealand (ANZ) region availability differs by country, so many patients still receive their first CD38 mAb at relapse. Because attrition across lines is substantial, therapy reserved for relapse may never be delivered. Randomized trials establish whether a CD38 mAb should be used, but not when patients first gain access to one. To our knowledge the line of first exposure has not been examined across a multinational cohort. We investigated the prognostic impact of CD38 mAb exposure within a given line, and whether the line of first exposure is associated with outcome.
Methods: The APAC and ANZ Myeloma & Related Diseases Registries (MRDR) are ongoing prospective cohorts of MM and related diseases in seven countries We analyzed newly diagnosed MM (extraction date, June 25, 2026) in two steps: Analysis 1 included 9,112 patients and compared those who did and did not receive a CD38 mAb-containing regimen within first-line (1L) and, separately, within the 3,394 who proceeded to second-line (2L) therapy; Cox models were adjusted for age category, ECOG performance status (PS), high-risk FISH, and clinical trial participation. Analysis 2 was restricted to the 2,336 CD38 mAb-exposed patients, assigned to mutually exclusive groups by the line in which the first CD38 mAb-containing regimen commenced (1L, 2L, or 3L/4L combined); use in later lines did not reassign a patient, and their distribution across countries and calendar periods examined. Because these cohorts enter follow-up at different disease stages, progression-free survival (PFS) and overall survival (OS) from first CD38 mAb initiation are reported descriptively within each cohort. For a comparison sharing a common time origin, OS was additionally measured from diagnosis, adjusted for age category, ECOG PS, and FISH risk category at diagnosis, with explicit missing-data categories. Kaplan-Meier and log-rank methods were used.
Results: Analysis 1. In 1L, 10.5% received a CD38 mAb-containing regimen; compared with those who did not, median PFS was 69.1 vs 34.5 months (log-rank P<.001) and the adjusted hazard ratio (HR) for exposure was 0.60 (95% CI, 0.50-0.71; P<.001), with adjusted OS HR 0.80 (95% CI, 0.63-1.01; P=.066). In 2L, 32.1% received a CD38 mAb-containing regimen; compared with those who did not, median PFS was 18.6 vs 14.9m (log-rank P<.001; adjusted HR, 0.89; 95% CI, 0.80-0.99; P=.028) and median OS 75.2 vs 44.5m (log-rank P<.001; adjusted HR, 0.86; 95% CI, 0.75-0.98; P=.029).
Analysis 2. First exposure was in 1L in 962 (41.2%), 2L in 1,061 (45.4%), and 3L/4L in 313 (13.4%); median follow-up was 18.7, 35.8, and 39.8m, respectively. First exposure differed markedly across countries (P<.001): in 1L in 70.7% of patients in China, 68.0% in Korea, 52.6% in Singapore, and 46.2% in Malaysia, but only 25.0% in Taiwan, 23.8% in Australia, and 21.2% in New Zealand. Exposure shifted toward earlier lines over time: first exposure was in 1L in 13.8% in 2020-2021, 26.9% in 2022-2023, and 55.9% from 2024 onward. Daratumumab monotherapy accounted for 1.7%, 6.1%, and 30.7% of regimens. ECOG PS >=2 (18.3%, 17.5%, 17.3%; P=.90) and eGFR <30 mL/min/1.73 m2 (17.1%, 14.5%, 14.2%; P=.24) were similar across groups. Within each cohort, median PFS from first initiation was 69.1, 18.6, and 6.9m and median OS 89.2, 75.2, and 25.7m for 1L, 2L, and 3L/4L, respectively. In an exploratory analysis using diagnosis as a common time origin, later first exposure was associated with higher mortality: adjusted HR, 1.58 (95% CI, 1.23-2.03) for 2L and 2.49 (95% CI, 1.89-3.26) for 3L/4L vs 1L (both P<.001).
Conclusions: CD38 mAb exposure was associated with longer PFS in both first and second line, and more so in first line. Among exposed patients, and despite immortal-time bias favoring those who reach later lines, later first exposure was associated with shorter OS when measured from diagnosis. These are prognostic associations rather than estimates of the independent effect of timing, and between-country differences are influenced by when each site began contributing to the registry. Frontline use has increased in recent years, and these findings support earlier introduction of CD38 mAb therapy, particularly where regulatory and reimbursement policy rather than clinical judgment determines the line at which it can first be given.
DISCLOSURES
Ji Hyun Lee, MD, PhD: Janssen - Other (including travel support); Takeda - Other (including travel support); Gilead - Honoraria; Novartis - Honoraria; Sanofi - Honoraria; Celgene-BMS - Honoraria; Janssen - Honoraria; Pfizer - Honoraria; Takeda - Honoraria; Amgen - Honoraria; Novartis - Research Funding; Janssen - Research Funding; Amgen - Research Funding; Janssen - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Gilead - Consultancy (Includes expert testimony); Celgene-BMS - Consultancy (Includes expert testimony); Pfizer - Speakers Bureau.; Janssen - Speakers Bureau.; Celgene-BMS - Speakers Bureau.; Sanofi - Speakers Bureau.; Takeda - Speakers Bureau.; Novartis - Speakers Bureau.; Amgen - Speakers Bureau.